Richards Group (RIC) Q2 2024 earnings summary

Executive summary

• Q2 revenue declined 1% year-over-year, mainly due to continued oversupply and weak demand in food & beverage packaging, partially offset by healthcare segment growth and improved product mix.

• Adjusted EBITDA rose by $1 million to 14% of sales, driven by higher margins from product mix shifts.

• Net income increased by $1 million, or $0.13 per unit, due to lower financial expenses and higher Adjusted EBITDA, despite a lower gain on exchangeable shares.

• Completed the acquisition of Insight Medical Technologies Inc. in late June, impacting the balance sheet.

Financial highlights

• Q2 revenue: $107.4 million, down from $108.9 million in Q2 2023; first half revenue: $205.3 million, down 4.8% year-over-year.

• Adjusted EBITDA for Q2: $15.1 million (14.1% of revenue), up from $14.4 million (13.2%) in Q2 2023.

• Net income for Q2: $11.8 million, up from $10.9 million; diluted EPS for Q2: $1.08, up from $1.00.

• Free cash flow in Q2: $6.7 million; $7 million used to repay debt and fund the Insight acquisition.

• Leverage ratio reduced to 0.1x from 0.2x at year-end 2023.

Outlook and guidance

• Management expects continued pressure on food and beverage packaging into Q3.

• Distributable cash flow sensitivity: $0.04 million for every 1¢ U.S./Cdn. exchange rate movement.

• Maintenance capital to be funded by operations at $0.4 million per quarter; $1 million set aside for IT upgrade.

• Surplus distributable cash in Q3 expected to be used for further debt reduction.